MARKET

EYEG

EYEG

EyeGate Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.830
+0.010
+0.55%
After Hours: 1.820 -0.01 -0.55% 19:57 09/22 EDT
OPEN
1.860
PREV CLOSE
1.820
HIGH
--
LOW
1.770
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
8.18
52 WEEK LOW
1.440
MARKET CAP
23.09M
P/E (TTM)
-1.0916
1D
5D
1M
3M
1Y
5Y
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares climbed 25.5% to $6.00. The company on Monday announced interim analysis from the Ph...
Benzinga · 09/14 16:04
NNVC, LIFE and DATS pre market gainers
Communications Systems JCS +27% declares $3.50 special dividend NanoViricides (NYSE:NNVC) +21% completes licensing for Coronavirus field which includes current COVID-19 drug development aTyr Pharma (NASDAQ:LIFE) +13%. DatChat (NASDAQ:DATS) +10%. SeaChange ...
Seekingalpha · 09/14 12:22
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Communications Systems, Inc. (NASDAQ: JCS) rose 34.8% to $9.15 in pre-market trading as the company declared a special dividend of $3.50 per share.
Benzinga · 09/14 11:13
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate's President and Chief Execu...
GlobeNewswire · 09/09 20:15
EyeGate Pharma Completes Target Enrollment In Phase 2 Proof-Of-Concept Study To Evaluate PP-001 For The Treatment Of Ocular Surface Inflammation
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases,
Benzinga · 09/08 10:55
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation
-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-
GlobeNewswire · 09/08 10:55
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
HC Wainwright & Co. Maintains Buy on Eyegate Pharmaceuticals, Lowers Price Target to $11
HC Wainwright & Co. analyst Yi Chen maintains Eyegate Pharmaceuticals (NASDAQ:EYEG) with a Buy and lowers the price target from $14 to $11.
Benzinga · 08/16 14:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EYEG. Analyze the recent business situations of EyeGate Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EYEG stock price target is 10.25 with a high estimate of 11.00 and a low estimate of 9.50.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 3.80M
% Owned: 30.11%
Shares Outstanding: 12.62M
TypeInstitutionsShares
Increased
4
85.57K
New
1
1.00K
Decreased
5
117.84K
Sold Out
2
12.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.11%
Key Executives
Chairman/Executive Director
Stephen From
President/Chief Executive Officer/Director
Brian Strem
Chief Financial Officer
Sarah Romano
Executive Vice President
Franz Obermayr
Lead Director/Independent Director
Paul Chaney
Independent Director
Kenneth Gayron
Independent Director
Aron Shapiro
Independent Director
Praveen Tyle
No Data
  • All
  • Financials
  • Insiders
More
About EYEG
Eyegate Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system. The Company's technology platform, PP-001, is a non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH). PP-001 has been developed in two clinical-stage ophthalmic formulations: PaniJect, is an intravitreal injection for inflammatory diseases of the eye including posterior uveitis, and PaniDrop, is a nano carrier technology eye drop for ocular surface diseases such as conjunctivitis, dry eye disease and others. The Company is also developing Ocular Bandage Gel (OBG), which is a form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity.

Webull offers kinds of Eyegate Pharmaceuticals Inc stock information, including NASDAQ:EYEG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYEG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYEG stock methods without spending real money on the virtual paper trading platform.